38 results about "Viral hepatitis" patented technology

Use of a compound in the treatment of liver diseases. Experimental results show that the compound has a relatively high liver-tissue-targeting property, very low toxicity to liver primary cells and high liver safety, has significant efficacy on liver diseases such as viral hepatitis (e.g., hepatitis B) and liver cancers (including primary liver cancers and metastatic liver cancers), and has relatively good physicochemical properties, metabolic stability, bioavailability and safety, thus having very good drug development prospects.

The invention discloses application of a compound in treatment of liver diseases. Experimental results show that the compound has relatively high liver tissue targeting property, very low toxicity to liver primary cells, high liver safety and obvious curative effects on liver diseases such as viral hepatitis (such as hepatitis B), liver cancer (including primary liver cancer and metastatic liver cancer) and the like; in addition, the compound also has better physicochemical properties, metabolic stability, bioavailability and safety, and has a very good drug development prospect.

The invention discloses a method for exploring the influence of hepatic hydatid on hepatitis, and belongs to the technical field of medical research. The method comprises the following steps: selecting liver echinococcosis cases and viral hepatitis cases from hospitals in areas with high incidence of echinococcosis; collecting detailed medical history data of the screened case patients; counting the collected data, establishing a database, comparing various index differences of hepatic hydatid combined hepatitis cases and pure viral hepatitis cases, and preliminarily analyzing the influence of hepatic hydatid on hepatitis; selecting a research object and pairing patients in a control group; establishing a follow-up visit queue, and regularly carrying out follow-up visit on the research object and the control group patients; and counting follow-up data of the research object and the control group of patients, and analyzing the influence of the hepatic hydatid on the hepatitis. According to the method for exploring the influence of the hepatic hydatid on the hepatitis, the influence of the hepatic hydatid on the hepatitis is comprehensively and deeply explored, and a powerful basis is provided for clinical diagnosis, treatment and prevention.

The present invention discloses an application of FN-1501 and its pharmaceutical composition in the preparation of drugs for preventing and / or treating liver injury, specifically including drugs for preventing and treating autoimmune hepatitis, viral hepatitis or drug-induced liver injury, especially drugs for preventing and treating autoimmune hepatitis. It can achieve multiple pharmacological effects of improving liver tissue structure damage, liver inflammation, reducing serum transaminase, serum lactate dehydrogenase and mRNA levels of inflammatory factors, and can play a therapeutic role at the gene level, molecular level and tissue level. There are no toxic side effects in the body, and the preparation form used is wide. The appropriate drug dosage form can be selected according to the clinical application scenario, which provides a new development strategy for targeted drugs for the prevention and treatment of liver injury.

To provide novel agents for the treatment or prevention of Epstein-Barr virus hepatitis. [Solution] A pharmaceutical composition for the treatment or prevention of Epstein-Barr virus hepatitis in a subject, comprising ibudilast, dipyridamole, or both as active ingredients.

The invention belongs to the technical field of biology, and particularly relates to application of an N-(quinoline-8-yl) quinoline-8-sulfonamide compound to preparation of a medicine for resisting hepatitis B virus. The structure of the compound comprises a salt as shown in (I) or pharmaceutically acceptable salt of the compound. The compound disclosed by the invention has a good inhibition effect on HBV virus replication on the cell level of HBV infection models such as HepG2.2. 15 and Huh7-NTCP, has anti-hepatitis virus activity, provides a good choice for treating viral hepatitis, and also has important significance for developing more ideal medicines for treating hepatitis B. # imgabs0 #

The invention belongs to the technical field of traditional Chinese veterinary medicines, and relates to a compound echinacea extract for treating duck virus hepatitis and a preparation method of the compound echinacea extract. The compound echinacea purpurea extract is prepared by mixing a traditional Chinese medicine concentrated extract and an echinacea purpurea extract according to a mass ratio of 4: (1-3), the traditional Chinese medicine concentrated extract is prepared from the following raw material medicines: radix bupleuri, radix isatidis, felwort, scutellaria baicalensis, cassia twig, angelica sinensis, oriental wormwood, radix puerariae and pericarpium citri reticulatae. The compound echinacea purpurea extract improves liver injury by improving the autoimmune function of ducks and exerting the antiviral effect of traditional Chinese medicines, and effectively prevents and treats duck viral hepatitis. The components of the composition are all from natural plants, and the composition is free of drug residues and drug resistance after long-term use, obvious in drug effect and small in toxic and side effect.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation and / or fibrosis in the liver, e.g., metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), primary biliary cholangitis, primary sclerosing cholangitis, alcoholic cirrhosis, hepatitis cirrhosis, cholestasis, autoimmune hepatitis, viral hepatitis B, viral hepatitis C, hemochromatosis, Wilson's disease, or alcoholic steatohepatitis, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.

The invention relates to the treatment of ascites, and especially refractory ascites, with an orally bioavailable prodrug of dopamine. A preferred prodrug of dopamine is docarpamine. In one embodiment treated patients are, prior to treatment, on doses of furosemide >80 mg / day and / or spironolactone >100 mg / day or equivalent doses of an alternative loop-acting and / or distal-acting diuretic. The ascites treated by the invention are typically caused by liver cirrhosis due to alcohol or non-alcoholic fatty liver disease and generally not due to viral hepatitis or primary biliary cholangitis. Typical patients have an activated renin-angiotensin-aldosterone levels as may be indicated by elevated levels of renin and / or aldosterone. Refractory ascites treatable according to the invention are such that patients beginning treatment require large volume paracentesis at a minimum of: (a) 3 times in 60 days, (b) 4 times in 90 days or (c) at least once every 30 days over a 90-day period. The invention also contemplates treating diuretic intractable ascites. Target plasma dopamine levels are disclosed by with dosing with the contemplated dopamine prodrugs may be guided. Preferred dosing is greater that 2250 mg per day, with more preferred doses exceeding 3500 mg per day.

To provide a NLRP3 activity regulator.SOLUTION: An activity regulator is characterized by a compound of formula AA or a pharmaceutically acceptable salt thereof. The compound of formula AA is NLRP3 activity regulator, and therefore, can be used for the treatment of metabolic disorder (e.g., TYPE 2 diabetes mellitus, atherosclerosis, obesity or gout), disease of central nervous system (e.g., Alzheimer disease, multiple sclerosis, amyotrophic lateral sclerosis or Parkinson disease), lung disease (e.g., asthma, COPD or idiopathic pulmonary fibrosis), liver disease (e.g., NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g., acute pancreatitis or chronic pancreatitis), kidney disease (e.g., acute nephropathy or chronic nephropathy), intestinal disease (e.g., Crohn's disease or ulcerative colitis), dermatosis, musculoskeletal disease (e.g., scleroderma), vascular disease, bone disease, eye disease (e.g., glaucoma or macular degeneration), disease originated from virus infection, autoimmune disease, cancer or aging.SELECTED DRAWING: None

The invention discloses application of licoflavone A in resisting viral hepatitis B, and belongs to the technical field of medicine application. The licoflavone A is used for treating viral hepatitis B. The licoflavone A used in the invention shows good safety and tolerance in HepG2.2. 15 and HepG2.A64 cells, can play a role in resisting HBV under the condition of no obvious cytotoxicity, and has significant advantages compared with interferon drugs in the prior art with long treatment course, large side effect and poor tolerance.

The application belongs to the technical field of biotechnology, and particularly relates to application of N-(quinoline-8-yl) quinoline-8-sulfonamide compounds in preparation of anti-hepatitis B virus drugs. The structure comprises as shown in (I) or a pharmaceutically acceptable salt thereof. The compound disclosed in the application has good inhibitory effect on HBV virus replication at the level of HBV infection model cells such as HepG2.2.15 and Huh7-NTCP, has anti-hepatitis virus activity, provides a good choice for treating viral hepatitis, and also has important significance for developing more ideal hepatitis B treatment drugs.

Aspects of the invention provide oral immediate release (IR) and / or extended release (ER) compositions comprising a therapeutically effective amount of aminodihydrophthalazinedione sodium (ADPS).

The present application belongs to the technical field of medicine, and particularly relates to a traditional Chinese medicine composition with the effect of preventing and / or treating hepatitis B. The traditional Chinese medicine composition is mainly prepared from Notopterygium incisum, Angelica pubescens, Poria cocos, Saposhnikovia divaricata, Schizonepeta tenuifolia, Chuanxiong, Platycodon grandiflorum, Bupleurum chinense, Peucedanum praeruptorum, Citrus aurantium, and Glycyrrhiza uralensis. The traditional Chinese medicine composition can not only significantly inhibit the activity of hepatitis B virus, but also significantly inhibit the secretion of HBSAg and HBeAg of hepatitis B virus, inhibit rebound after drug withdrawal, has a significant preventive and / or therapeutic effect on liver damage caused by hepatitis B virus infection, and can promote the production of hepatitis B surface antibody, thus having a broad clinical application prospect.

The application discloses an anti-hepatic fibrosis small-molecule compound and application, which is composed of 3beta-ethoxy artenimol and 6-hydroxy kaempferol, and is used as an anti-hepatic fibrosis drug after splenectomy. The application can improve the hepatic fibrosis degree after splenectomy (reduce liver inflammation, improve liver enzyme spectrum, reduce bilirubin, and reduce collagen deposition), and the causes of liver fibrosis include at least one of alcoholic hepatitis, fatty liver, viral hepatitis, drug-induced hepatitis, autoimmune hepatitis and the like.

The invention discloses a preparation method of alpha-ketoisovaleric acid in an anti-hepatic fibrosis drug, and relates to the technical field of hepatic fibrosis treatment drug development, and the preparation method comprises the following steps: mixing alpha-ketoisovaleric acid with pharmaceutic adjuvants to prepare a pharmaceutically acceptable dosage form; the dosage of the alpha-ketoisovaleric acid is determined based on the pharmacological activity of the alpha-ketoisovaleric acid in the concentration range of 50 mu M to 200 mu M, wherein the alpha-ketoisovaleric acid can inhibit hepatic stellate cell activation induced by a transforming growth factor-beta; an endogenous metabolite alpha-ketoisovaleric acid is applied to preparation of an anti-hepatic fibrosis medicine, and based on the pharmacological activity of the alpha-ketoisovaleric acid for specifically inhibiting activation of TGF-beta induced hepatic stellate cells at the concentration of 50-200 mu M, a novel anti-hepatic fibrosis preparation which is high in safety, wide in therapeutic window and free of liver and kidney accumulation risk is developed. The medicine is not only suitable for treating hepatic fibrosis caused by various causes such as non-alcoholic fatty liver disease, viral hepatitis, alcoholic liver disease and drug-induced liver injury, but also meets the requirements of early intervention and severe treatment through reasonable dosage form design and administration route selection.

The invention relates to the technical field of microorganisms, in particular to a highly pathogenic duck virus hepatitis III virus and an egg yolk antibody, preparation and application thereof. The virus strain is preserved in the China General Microbiological Culture Collection Center (CGMCC) on December 24, 2024, the preservation number is CGMCC No.46271, and the virus strain is named as RD240820B. The egg yolk antibody is prepared by using the highly pathogenic duck virus hepatitis III type virus strain as an antigen. The egg yolk antibody is applied to preparation of products for preventing or treating duck virus hepatitis III. In a virulence experiment on a duck embryo, the death rate of the virus strain reaches 80% after the duck embryo is inoculated for 36 hours, and the virus strain has strong pathogenicity. And the death rate within 60 hours after inoculation is 100%, and the strain has relatively strong pathogenicity. The death rate is still 60% when the diluent is 10-8, and the toxicity is strong. The ELD50 value of the strain is relatively low, which indicates that the strain has relatively strong pathogenicity to duck embryos. After the egg yolk antibody is injected, the protection rate reaches up to 97.6% after the diseased duck is treated, and the egg yolk antibody has a remarkable prevention and control effect.

The invention discloses a traditional Chinese medicine preparation for treating hepatopathy and a preparation method thereof, and relates to the technical field of traditional Chinese medicines. According to the traditional Chinese medicine preparation for treating liver diseases and the preparation method thereof, the traditional Chinese medicine preparation comprises the following components in parts by weight: 20-35 parts of cordyceps militaris, 10-25 parts of radix puerariae, 10-18 parts of rhizoma smilacis glabrae, 5-12 parts of prismatomeris tetrandra, 15-25 parts of oxtail, 5-8 parts of lucid ganoderma, 12-24 parts of schisandra chinensis, 4-9 parts of hovenia dulcis thunb and 20-25 parts of salvia miltiorrhiza. The traditional Chinese medicine has a remarkable effect on treating viral hepatitis and alcoholic hepatitis, also plays a role in maintaining the spleen and kidney of a patient in the process of treating liver diseases, has no toxic or side effect after being used for a long time, has the effects of reducing the fat content of the liver and improving the lipid metabolism capability of the liver, and also can play the effects of protecting and nourishing the liver before and after drinking; meanwhile, the added components such as cordyceps militaris, the root of kudzu vine, the root of red-rooted salvia, lucid ganoderma and the like are cooperated to play a certain role in blocking and preventing liver canceration of a user.

The invention relates to the treatment of ascites, and especially refractory ascites, with an orally bioavailable prodrug of dopamine. A preferred prodrug of dopamine is docarpamine. In one embodiment treated patients are, prior to treatment, on doses of furosemide >80 mg / day and / or spironolactone >100 mg / day or equivalent doses of an alternative loop-acting and / or distal-acting diuretic. The ascites treated by the invention are typically caused by liver cirrhosis due to alcohol or non-alcoholic fatty liver disease and generally not due to viral hepatitis or primary biliary cholangitis. Typical patients have an activated renin-angiotensin-aldosterone levels as may be indicated by elevated levels of renin and / or aldosterone. Refractory ascites treatable according to the invention are such that patients beginning treatment require large volume paracentesis at a minimum of: (a) 3 times in 60 days, (b) 4 times in 90 days or (c) at least once every 30 days over a 90-day period. The invention also contemplates treating diuretic intractable ascites. Target plasma dopamine levels are disclosed by with dosing with the contemplated dopamine prodrugs may be guided. Preferred dosing is greater that 2250 mg per day, with more preferred doses exceeding 3500 mg per day.

The invention belongs to the technical field of biology, and particularly relates to a recombinant baculovirus capable of simultaneously expressing gene type 1 and gene type 3 duck hepatitis A virus VP1 protein and application of the recombinant baculovirus in preparation of a duck hepatitis A divalent subunit vaccine. The recombinant baculovirus co-expressing the gene type 1 and gene type 3 duck hepatitis A virus VP1 protein is constructed, the virus titer is high, and the two proteins can be expressed. Therefore, the recombinant baculovirus provided by the invention can be used for research and development and epidemic disease prevention and control of novel vaccines for duck viral hepatitis A.

The invention discloses a composite liver and kidney protective agent as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The protective agent is prepared from 10%-20% of inosine, 15%-25% of glutamic acid, 10%-15% of cysteine, 15%-20% of glycine, 5%-10% of a coenzyme compound, 10%-20% of small molecule peptide and auxiliary materials. The preparation method comprises the steps of premixing, low-temperature homogenization, spray drying and preparation forming, and uniform distribution of components is ensured through a spray drying technology. The traditional Chinese medicine composition plays a role through a three-stage mechanism of fat removal, repair and regeneration, reduces lipid deposition, scavenges free radicals, repairs hepatocytes and promotes regeneration. The traditional Chinese medicine composition can be used for treating or preventing liver and kidney diseases such as non-alcoholic fatty liver, viral hepatitis and cirrhosis, relieving symptoms such as anorexia, jaundice and bleeding, dispelling the effects of alcohol, protecting the liver and enhancing immunity. The proportion of natural components of the protective agent is more than 80%, the safety is high, multiple targets are synergistic, and the curative effect is superior to that of a single-component medicine.

The application discloses a composition for preventing non-viral hepatitis and a preparation method and application thereof, and belongs to the technical field of food processing. The composition comprises a crude peptide, and the amino acid sequence of the crude peptide is Ile-Val-Tyr-Pro-Trp-Thr-Gln-Arg; further comprises lipids and excipients; the crude peptide and the lipids form a water-in-oil emulsion system; and the emulsion system and the excipients are mixed to form the composition. Experiments prove that the composition prepared by the application has the effect of improving non-viral hepatitis, and provides a new way for the prevention and treatment of non-viral hepatitis.

This invention relates to a novel use of synephrine in the preparation of drugs for treating cholestatic liver disease, belonging to the field of pharmaceutical technology. Cholestatic liver disease is characterized by jaundice and conjugated bilirubin and / or total bilirubin hyperconjugation caused by impaired bilirubin excretion due to various reasons. Its causes include common bile duct stones, pancreatic duct cancer, common bile duct malignant tumors, pancreatic cancer, biliary parasitic diseases, viral hepatitis cirrhosis, alcoholic liver disease, fatty liver disease, drug-induced liver injury, primary biliary cirrhosis, intrahepatic sclerosing cholangitis, and certain congenital diseases such as Dubin-Johnson syndrome and Rotor syndrome. This invention establishes a mouse cholestasis model using bile duct ligation and administers synephrine by gavage to evaluate its protective effect against liver injury. The results showed that synephrine significantly improved jaundice caused by cholestasis, reduced hepatocellular necrosis and inflammatory infiltration caused by cholestasis, alleviated bile duct dilation, decreased serum total bilirubin (TBIL) and direct bilirubin (DBIL), and reduced the levels of total bile acids (BA) in liver tissue and plasma. Furthermore, the above-mentioned effects of synephrine in improving cholestasis showed a clear dose-dependent effect. This invention reveals for the first time the application of synephrine in cholestatic liver disease, demonstrating good safety and promising clinical development prospects.

To provide a method for treating viral hepatitis caused by infection with hepatitis delta virus (HDV).SOLUTION: The present invention provides a method for reducing hepatitis delta virus (HDV) viral load in a human patient with an HDV infection. The method comprises treating the patient with lonafarnib-ritonavir co-therapy for at least 30 days, where the patient has a baseline viral load of at least 105 IU / mL serum before the initiation of treatment, and the treatment results in a reduction of viral load to less than 103 IU / mL serum. In the method, the HDV viral load remains at the level less than 103 IU / mL serum for at least one month after the treatment.SELECTED DRAWING: None

The invention relates to a gosling plague and duck virus hepatitis bivalent egg yolk antibody as well as a preparation method and application thereof. The vaccine is prepared from a gosling plague virus antigen part and a duck virus hepatitis virus antigen part, the gosling plague virus antigen part is a gosling plague virus HVFS22 strain, and the duck virus hepatitis virus antigen part comprises a duck virus hepatitis virus type 1 HVSD20 bead and a duck virus hepatitis virus type 3 HVGZ22 bead. The egg yolk antibody can provide immune protection for gosling plague virus and duck virus hepatitis virus (type 1 and type 3) at the same time, the tedious procedure of inoculating various vaccines is reduced, and the breeding efficiency is improved; a high-purity and high-titer specific antibody is adopted, so that the vaccine can quickly generate immune reaction in an animal body and has relatively strong resistance to infection of corresponding viruses; through strict quality control in the preparation process, possible harmful substances can be effectively removed by adopting an antibody purification technology, so that not only is the emergency treatment effect improved, but also the occurrence rate of adverse reactions after vaccination is greatly reduced.

The present invention discloses a curdlan fullerene derivative, its preparation method, and application. The curdlan fullerene derivative comprises curdlan and a fullerene derivative, wherein the curdlan and the fullerene are covalently synthesized by amidation. The curdlan is a water-soluble curdlan derivative, and the fullerene is a carboxylated fullerene derivative. The curdlan fullerene provided by the present invention can efficiently scavenge free radicals, protect cells, and reduce oxidative damage. The curdlan fullerene material of the present invention can be used to treat liver-related diseases such as autoimmune hepatitis, viral hepatitis, liver damage, cirrhosis, hepatic steatosis, and other liver diseases through intravenous administration, intraperitoneal administration, and the like.

The invention belongs to the technical field of traditional Chinese medicine agentia, and discloses a medicine for treating viral hepatitis B. The medicine comprises the following components: oriental wormwood, lysimachia christinae hance, honeysuckle, radix paeoniae rubra, rhizoma corydalis, endothelium corneum gigeriae galli, polygonum cuspidatum, semen raphani, oldenlandia diffusa, turtle shell, astragalus membranaceus, cortex moutan, medlar, dandelion, patrinia, glossy privet fruit, radix bupleuri, fried malt, hawthorn and medicated leaven. Based on the principle of treating viral hepatitis B in traditional Chinese medicine, liver function indexes are improved through oriental wormwood, lysimachia christinae hance and polygonum cuspidatum, and hepatitis B virus replication is inhibited through honeysuckle, oldenlandia diffusa and patrinia; the astragalus membranaceus, the glossy privet fruit and the medlar are used for regulating the immune function and enhancing the body resistance; the turtle shell, the radix paeoniae rubra and the cortex moutan are used for promoting blood circulation to remove blood stasis and improving hepatic fibrosis; the endothelium corneum gigeriae galli, the roasted malt, the hawthorn and the medicated leaven are used for invigorating spleen to promote digestion and improving medicine absorption, and compared with the traditional western medicine, the traditional Chinese medicinal materials have a synergistic effect and can help to treat the viral hepatitis B.

The invention discloses an application of alzovudine in resisting viral hepatitis B, and belongs to the technical field of medicine application. The alzovudine is used for treating and resisting viral hepatitis B. An in-vivo and in-vitro combined efficacy verification system is established, a multi-genotype and drug-resistant mutation HBV model is covered, experimental results are stable and repeatable, and screening and evaluation of novel nucleoside anti-HBV drugs can be effectively guided. The invention reveals that the FNC has the comprehensive technical advantages of broad-spectrum virus resistance, drug-resistant mutation resistance, strong antigen removal capability, high safety and the like in the treatment of hepatitis B virus infection, breaks through the bottleneck that the existing NAs has limited curative effect and the antigen is difficult to remove, and provides a new candidate drug and a technical route for functional cure of chronic hepatitis B.

The invention discloses an application of a fortune euonymus herb chemical fiber formula in treatment of hepatic fibrosis, and relates to the field of biological medicines. According to the present invention, the anti-hepatic fibrosis effect is provided by inhibiting hepatic stellate cell activation and reducing extracellular matrix deposition, and the hepatic fibrosis is the chronic liver injury pathological stage caused by viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease or drug-induced liver injury; in an in-vitro experiment, the euonymus fortunei chemical fiber formula also plays a role in resisting hepatic fibrosis by inhibiting a transient receptor potential vanillic acid subtype 4 signal channel. The method has the following comprehensive advantages that (1) HSC activation and ECM deposition are inhibited through multi-component and multi-target cooperation; (2) key signal channels such as TGF-beta1 / Smad, TRPV4 and the like can be regulated and controlled at the same time; (3) liver function indexes are obviously improved, and tissue structure damage is relieved; and (4) the medicine is natural in source, high in safety and suitable for long-term application.